Eurosurveillance is a prestigious journal dedicated to the field of epidemiology, public health, and infectious diseases, published by the European Centre for Disease Prevention and Control since 1996. With an impressive Q1 ranking across various categories, including Epidemiology and Public Health, it consistently stands at the forefront of research dissemination, making it an invaluable resource for researchers, professionals, and students alike. The journal boasts an outstanding reputation, as evidenced by its Scopus rankings, where it ranks in the top 1% to 3% in multiple relevant categories. As an Open Access publication, Eurosurveillance ensures that vital findings are freely accessible to a global audience, fostering collaboration and innovation in the fight against infectious diseases. With a dedicated reach from 2001 to 2024, the journal addresses contemporary challenges in public health and virology, reinforcing its significance in shaping policies and research initiatives across the world.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Clinical Infectious Diseases, published by Oxford University Press Inc, is a premier journal in the fields of infectious diseases and microbiology, distinguished by its esteemed Q1 ranking in both categories as of 2023. Since its inception, the journal has served as a vital platform for disseminating cutting-edge research and significant advancements in the diagnosis, treatment, and prevention of infectious diseases. With a broad scope encompassing clinical trials, epidemiological studies, and public health research, it targets a diverse readership, including researchers, healthcare professionals, and students. The journal's robust reputation is underscored by its impactful contributions to scientific understanding, making it a critical resource for those striving to combat infectious diseases globally. Clinical Infectious Diseases is not open access but offers various subscription options, ensuring comprehensive access to its high-quality content. With a historical continuity from 1985 to present, the journal remains at the forefront of medical research, paving the way for future innovations in the field.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

JOURNAL OF MEDICAL VIROLOGY is a prestigious academic publication dedicated to advancing the field of virology and infectious diseases. Published by WILEY, this journal has established itself as a cornerstone within the scientific community since its inception in 1977, and it will continue to provide cutting-edge research until 2024. With an impressive impact factor that places it in the Q1 quartile for both Infectious Diseases and Virology, the journal ranks 14 out of 344 in Medicine - Infectious Diseases and 6 out of 80 in Immunology and Microbiology - Virology according to Scopus metrics. Its focus encompasses a broad spectrum of topics, including viral pathogenesis, diagnostics, treatment strategies, and epidemiology, making it an essential resource for researchers, clinicians, and students alike. Although not an open-access journal, it provides valuable insights and accessible content for subscribers and libraries. The ongoing commitment to high-quality peer-reviewed articles makes JOURNAL OF MEDICAL VIROLOGY a vital platform for disseminating knowledge and fostering innovation in virology and related fields.

Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.